Navigation Links
Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years
Date:9/28/2007

instruments used in Urology, Acute Care, Primary Care, and Extended Care. BladderScan(R) helps diagnose urinary-related problems such as enlarged prostate (BPH) and overactive bladder (OAB), and is clinically proven to prevent unnecessary urinary catheterizations and reduce rates of urinary tract infection. The company also manufactures and markets the innovative GlideScope(R) video laryngoscope (GVL(R)). GlideScope(R) provides a consistently clear view of the airway, enabling quick intubation, and offers significant benefits to Anesthesiology, Emergency, Critical Care, EMS professionals. GlideScope(R) is also being used by the military in both Afghanistan and Iraq.

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2002 and $5,000,000 in 2006, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.

Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit http://www.fast500.com.

About Verathon Inc.

Verathon(R), formerly Diagnostic Ultrasound Corp., designs and manufactures reliable, state-of-the-art medical devices and services that offer a meaningful improvement in patient care to the health care community. The company's noninvasive BladderScan(R) instrument is the standard of care for bladder volume measu
'/>"/>

SOURCE Verathon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Researchers identify the early makers of Neonatal Sepsis
2. New pacemaker reduces risk of heart failure
3. Epilepsy Patients Could Benefit From Pacemakers
4. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
5. Stem Cells Could Replace Electronic Pacemakers
6. Lawmakers alerted on new tobacco control policies by research team
7. Novel Biological Pacemaker Under Construction for Weak Hearts
8. Chocolate makers to be health wise and urge consumers to be too!
9. Drug Makers Banned From Providing Gifts To Doctors
10. Knowing spread of AIDS: a crime; urges Chinese lawmaker.
11. Lawsuit Against Sunscreen Makers For False Claims of Protection Against Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008).../ -- The Providence Service,Corporation (Nasdaq: ... Company,s,Chief Operating Officer, has been appo...orris, appointment fills the vacancy left by the A...eturns the board to six members. Mr.,Norris will... Mr. Norris, age 41, has been with Providence sinc...
(Date:11/21/2008)...que to combat cancer, study says, , ,...rchers have discovered that some cancer cells use ...ght lead to new treatments that starve and kill th...lls in the body need to produce energy. They do th...ires oxygen. Compared with normal cells, tumor cel...
(Date:11/21/2008)...ect Investment And Restore Shareholder Value , ...-- Dr. Stephen Joffe, Craig Joffe, and Alan Buckey...th the U.S. Securities and Exchange Commission. T...ip of 11.4% of LCA-Vision, Inc. (Nasdaq: LCAV ),...on correction centers in 33 states in the United S...
(Date:11/21/2008)...l/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL ) to... approved the proposals submitted to them relating...s Industries Ltd. (Nasdaq: TEVA ). , , "... of the transaction by the Barr shareholders," sai...e pleased with the progress that we continue to ma...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
... year received gifts for Christmas that may result...ly confine children to their houses and thereby ma...t Wales Institute of Higher Education (NEWI) revea...kids. X-mas gifts fail to encourage children to go...
...nne Murabito and team have reported that the risk ...ho have their siblings with heart disease.// Thoug...t disease is genetically susceptible and risk incr...dy has shown a 45% increased risk of heart disease...
...ng comes a study that states that about one-third ...o 49 years) in the U.S. have poor cardio respirato...holesterol and blood pressure levels. The study is...JAMA. There has been a strong correlation betwee...
...on children’s will be hi-tech whiz kids but would ...o indoor games with no physical activity.// A surv...er Education found that there is an increase in ob...nd poor diet rich in fatty foods due to fast food....
Other Medicine News:
(Date:11/20/2008)...swire-FirstCall/ -- Duska Therapeutics,Inc., (OT...as submitted its,pivotal Phase 3 ATPace clinical ...l Assessment (SPA) procedure with the U.S. Food an...securing an agreement with the FDA, Duska intends ...placebo-controlled and randomized Phase 3,clinica...
(Date:11/20/2008)...tCall/ -- PAREXEL International Corporation (Nasda...rvices provider, today announced that it has opene...nsulting and clinical research capabilities. With ...ocations throughout five important biopharmaceutic...gentina, Brazil, Chile, and Mexico. This expansion...
(Date:11/19/2008)...PRNewswire-FirstCall/ -- Amgen,(Nasdaq: AMGN ) ...sidiary of,Takeda Pharmaceutical Company Limited ...he Phase 3 MONET1 trial evaluating motesanib (AMG ...in for the first-line treatment of,advanced non-s... suspended,following a planned safety data review...
(Date:11/19/2008)...ewswire/ -- Biotech scientists increasingly are ap...h to better understand the effects of novel drug c...Genetic Engineering & Biotechnology News ( GE...t a new compound,s mechanism of action and eventua...according to the November 15 issue of GEN . ( htt...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2World Famous DavidBartonGym Buffs up the Bravern 12788 1World Famous DavidBartonGym Buffs up the Bravern 12788 2World Famous DavidBartonGym Buffs up the Bravern 12788 3Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 1Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 2Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 3Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 4Plexus Systems Inc Names Stosz to Solutions Engineer 12783 1Plexus Systems Inc Names Stosz to Solutions Engineer 12783 2Plexus Systems Inc Names Khanna to Senior Account Manager Western Region 12779 1Plexus Systems Inc Names Khanna to Senior Account Manager Western Region 12779 2
...INESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals...essor of,Pharmacology and Executive Vice President...tute at Albany College of Pharmacy,will present n...ombotic effect of Othera,s lead compound, OT-551, ... previous ocular,studies on OT-551 eye drops, as w...
..., April 19, 2007 /PRNewswire-FirstCall/ --,CuraGen...at,preliminary interim clinical data on intravenou...) inhibitor being investigated,for the treatment o...ming major medical meetings. , One oral and one po...lts with belinostat will be made at the 2007 Ameri...
Other Medicine Technology:Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 2Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 3Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5
Wet-Field Hemostatic Eraser bipolar tip, packsize is 5/box.
Sterile cordless eraser tips, packsize is 10/box.
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium.
Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium.
Medicine Products: